Menu
Washingtoner
  • Home
  • Business
  • Construction
  • Technology
  • Arts
  • Health
  • Property
  • Software
  • Real Estate
Washingtoner

Omeros Announces Online Publication in Advance of ASH Annual Meeting Detailing Narsoplimab Treatment Under Compassionate Use of 15 Patients with Hematopoietic Stem Cell Transplant-associated Thrombotic Microangiopathy
Washingtoner/10237740

Trending...
  • K Spa in Bellevue Now Accepts HSA and FSA for Medically Necessary Massage Therapy
  • Spokane: Mayor Brown Announces Proposals to Jumpstart New Affordable Housing Developement
  • Consumer Accountability Alliance Issues Formal Notice Alleging Proximate Liability for Medical Harm
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced online publication of a report detailing treatment with narsoplimab of 15 adult and pediatric patients with hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA), 14 of whom had "high-risk" TA-TMA. Narsoplimab is Omeros' investigational antibody targeting MASP-2, the effector enzyme of the lectin pathway of the complement system. The report was authored by an external group of investigators involved in the treatment of these patients with narsoplimab provided under Omeros' compassionate use program.

The report will be featured as a poster presentation at the 65th Annual Meeting of the American Society of Hematology (ASH), to be held December 9-12, 2023 in San Diego. The abstract (#3543) is available on the ASH website at www.hematology.org or by clicking here.

The poster will be presented by Dr. Marta Castelli, Department of Oncology and Hematology, University of Milan and Azienda Socio-Sanitaria Territoriale Papa Giovanni XXIII, Bergamo, Italy. Details of the presentation are as follows:

Clinical Safety and Efficacy of Narsoplimab in Pediatric and Adult Patients with Transplant-Associated Thrombotic Microangiopathy: A Real-World Experience (Abstract #3543)
Session Name: 721. Allogeneic Transplantation: Conditioning Regimens, Engraftment and Acute Toxicities: Poster II
Date: Sunday, December 10, 2023
Presentation Time: 6:00 p.m. - 8:00 p.m. PT

More on Washingtoner
  • Revolutionary Blockchain Platform Okh Finance Announces Okh Finance(OKKH) Token Launch to Transform Global Asset Leasing Market
  • Cover Girl Finalist Teisha Mechetti Questions Legitimacy of Inked Originals Competition, Demands Transparency
  • Spokane: National Night Out Against Crime is August 5th
  • Easton & Easton, LLP Files Suit Against The Dwelling Place Anaheim & Vineyard USA Over Abuse Allegations
  • AI Visibility: The Key to Beating Google's AI Overviews and Regaining Traffic

Location: San Diego Convention Center, Halls G-H

About Narsoplimab

Narsoplimab, also known as "OMS721," is an investigational fully human monoclonal antibody targeting mannan-binding lectin-associated serine protease-2 (MASP-2), a novel pro-inflammatory protein target and the effector enzyme of the lectin pathway of complement. Importantly, inhibition of MASP-2 has been demonstrated to leave intact the antibody-dependent classical complement activation pathway, which is a critical component of the acquired immune response to infection. A biologics license application (BLA) is pending before the U.S. FDA for use of narsoplimab in the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA), and Omeros expects to resubmit the BLA to include additional information supporting approval of narsoplimab in this indication. Narsoplimab is also in clinical development programs focused on other complement-mediated disorders, including COVID-19. FDA has granted narsoplimab breakthrough therapy and orphan drug designations for TA-TMA and orphan drug status for the prevention (inhibition) of complement-mediated thrombotic microangiopathies as well as for the treatment of TA-TMA. The European Medicines Agency has granted orphan drug designation to narsoplimab for treatment in hematopoietic stem-cell transplant.

About Omeros Corporation

Omeros is an innovative biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. Omeros' lead MASP-2 inhibitor narsoplimab targets the lectin pathway of complement and is the subject of a biologics license application pending before FDA for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy. Omeros' long-acting MASP-2 inhibitor OMS1029 is currently in a Phase 1 multi-ascending dose clinical trial. OMS906, Omeros' inhibitor of MASP-3, the key activator of the alternative pathway of complement, is advancing in clinical programs for paroxysmal nocturnal hemoglobinuria and complement 3 glomerulopathy. Funded by the National Institute on Drug Abuse, Omeros' lead phosphodiesterase 7 inhibitor OMS527 is in clinical development for the treatment of cocaine use disorder and, in addition, is being developed as a therapeutic for other addictions as well as for a major complication of treatment for movement disorders. Omeros also is advancing a broad portfolio of novel immuno-oncology programs comprised of two cellular and three molecular platforms. For more information about Omeros and its programs, visit www.omeros.com

More on Washingtoner
  • Stuck Doing Math or Figuring Out Life's Numbers? Calculator.now Makes It Stupidly Simple
  • Spokane: Mayor Brown Urges Federal Lawmakers to Save the Community Development Block Grant (CDBG) Program
  • Colbert Packaging Announces WBENC Recognition
  • DivX Empowers Media Enthusiasts with Free Expert Guides for Advanced MP4 Management
  • Assent Expands Executive Team to Accelerate Global Growth & Innovation

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, which are subject to the "safe harbor" created by those sections for such statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as "anticipate," "believe," "expect," "intend," and similar expressions and variations thereof. Forward-looking statements, including statements regarding Omeros' investigational drug candidates, anticipated next steps in relation to the biologics license application for narsoplimab or in relation to other development programs are based on management's beliefs and assumptions and on information available to management only as of the date of this press release. Omeros' actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, without limitation, unanticipated or unexpected outcomes of regulatory processes in relevant jurisdictions, unproven preclinical and clinical development activities, the Company's financial condition and results of operations, regulatory processes and oversight, challenges associated with manufacture or supply of our investigational or clinical products, intellectual property claims, competitive developments, litigation, and the risks, uncertainties and other factors described under the heading "Risk Factors" in the company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 13, 2023. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and the company assumes no obligation to update these forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

Contacts

Jennifer Cook Williams
Cook Williams Communications, Inc.
Investor and Media Relations
IR@omeros.com
Filed Under: Business

Show All News | Report Violation

0 Comments
1000 characters max.

Latest on Washingtoner
  • Heritage at South Brunswick Offers Immediate Townhome Appointments and Special Mortgage Incentive Fast-Moving Sales
  • City of Spokane Announces New Deputy Police Ombuds
  • NASA Collaborative Agreement for Supply of Thin-Film Solar Tech for Orbital Application to Advance Development of Thin-Film PV Power Beaming: $ASTI
  • Exciting New Era of Sports, Entertainment & Gaming Innovation Spotlighted by Rebrand of Expanding AI Driven, Online Fan Engagement Company: SEGG Media
  • Service Ninjas Debuts First-of-Its-Kind "Membership" Platform for Home Service Pros
  • BIYA Forecasts 2025 Surge with ¥300M ($41.8 M USD) in Revenue and ¥25M Profit from Cloud Based HR Solutions: Baiya Intl. Group (N A S D A Q: BIYA)
  • Paul E. Saperstein Co. Announces Geographic Expansion of Auction Services
  • Florida Broker Bent Danholm Featured in the Daily Mail's U.S. Real Estate Coverage
  • Robin Launches Legal Intelligence Platform to solve intelligence gap in Fortune 500 legal teams
  • Melissa B. Releases Digitally Independent: Empowering Music Artists with AI and Brand Strategy
  • Consumer Accountability Alliance Issues Formal Notice Alleging Proximate Liability for Medical Harm
  • Utah Metal Fabricator Titan Forge Builds Momentum with Custom Steel Projects and Spiral Staircases
  • K Spa in Bellevue Now Accepts HSA and FSA for Medically Necessary Massage Therapy
  • Jason Koch: Pioneering the Future of Real Estate Development in New Jersey
  • Spokane: Mayor Brown Announces Proposals to Jumpstart New Affordable Housing Developement
  • Bach and Beyond: Cellists Return to the Beach for 2nd Annual Bethany Beach Cellofest
  • Spokane: False report of a shooting causes temporary delay at Riverfront Park during 4th of July celebration
  • PCL Construction Appoints Tyler Kautz to Lead Data Center Expansion Amid $1.3 Trillion Market Boom
  • NR7 Miner launches zero-cost USDT cloud mining service: daily stable income + referral rewards for double profit
  • Larry Haight's Residential Roofing Celebrates 40 Years of Excellence in the Pacific Northwest
_catLbl0 _catLbl1

Popular on Washingtoner

  • Experience Trembling Firsthand with the New AgeMan® Tremor Simulator - 232
  • ASI Accelerates iMIS® Innovation by Acquiring CSI's Product Suite and Expert Team - 193
  • Keebos Launches New Universal Pearl Strap That Attaches to Any Phone Case - 179
  • Integris Composites Joins Paris Air Show at USA Pavilion - 159
  • Last Call - Submit Your Proposal for the 2025 OpenSSL Conference in Prague - 152
  • Patrick Aloni Joins Historic Gold and Copper Discovery in Argentina with Multimillion-Dollar Stake - 135
  • Sploot Vets and DeepScan Launch Exclusive Regional U.S. Partnership to Bring Breakthrough Pet DNA Test to Market - 117
  • Evluma and LED Roadway Lighting Ltd. Join Forces to Drive Innovation - 110
  • purelyIV Blog Named One of the Top 45 IV Therapy Blogs by Feedspot
  • GMO Miner: Creating a simple, efficient and reliable new cloud mining experience

Similar on Washingtoner

  • The Blue Luna Encourages Local Schools to Take Steps to Enhance Safety for Students and Staff
  • Smart Resnse Unveils Smart Resnse(SRMS) Token-Powered AI Orchestration Platform to Revolutionize Multi-Billion Dollar Market
  • Cover Girl Finalist Teisha Mechetti Questions Legitimacy of Inked Originals Competition, Demands Transparency
  • The World's Largest Green Economic Revolution Emerges as Nature, Tech, and Finance Converge
  • Pyro Marketing Opens New Digital Marketing Company in Saint Petersburg to Power Growth for Fitness and Ecommerce Brands
  • Dr. John Salerno of Salerno Wellness Introduces Their New Full Body Capsule for Advanced LED Light Therapy Patient Treatments
  • Alaska Air Group announces webcast of second-quarter 2025 financial results
  • Adostics & Genmega Announce the Introduction of A-POD
  • Erie Home Celebrates 100th Location, Cementing Coast-to-Coast Footprint
  • LIB and Nidec Rejoin Forces for Giant TH-0098 Temperature Humidity Test Chamber
Copyright © 2025 washingtoner.com | Terms of Service | Privacy Policy | Contact Us | Contribute